







































Association between higher pericoronary adipose
tissue attenuation measured by coronary
computed tomography angiography and
nonalcoholic fatty liver disease
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Abstract
Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cardiac mortality. Pericoronary adipose tissue (PCAT) attenuation,
expressed by the fat attenuation index on coronary computed tomography angiography, reflects pericoronary inflammation. We
aimed to investigate the association between PCAT attenuation and NAFLD.
This is a single-center cohort study comprising of patients who underwent coronary computed tomography angiography for
suspected stable coronary artery disease between January and December 2020. Patient characteristics and coronary computed
tomography angiography findings were analyzed between patients with NAFLD (n=78) and a propensity score-matched cohort of
patients without NAFLD (n=78). PCAT attenuation was assessed in Hounsfield units (HU) of proximal 40-mm segments of the left
anterior descending artery (LAD) and right coronary artery.
The mean PCAT attenuation in LAD and right coronary artery were significantly higher in patients with NAFLD than those without
NAFLD. When patients were divided into 2 groups using the median LAD-PCAT attenuation of72.5 HU, the high PCAT attenuation
group had more males (82% vs 67%, P= .028) and NAFLD patients (63% vs 37%, P= .001) compared to the low PCAT attenuation
group. No differences in age, body mass index, conventional cardiovascular risk factors, or the presence of high-risk plaque were
observed between the 2 groups. In the multivariate logistic analysis, NAFLD was independently associated with high PCAT
attenuation (odds ratio 2.912, 95% confidence interval 1.386 to 6.118, P= .005).
NAFLD is associated with high PCAT attenuation on coronary computed tomography angiography. This finding suggests that
pericoronary inflammation is involved in the increased cardiac mortality in NAFLD patients.
Abbreviations: CTA = computed tomography angiography, LAD = left anterior descending artery, NAFLD = nonalcoholic fatty
liver disease, PCAT = pericoronary adipose tissue, RCA = right coronary artery.
Keywords: coronary computed tomography angiography, non-alcoholic fatty liver disease, perivascular coronary inflammation
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common
liver disease, with an estimated prevalence of 15% to 30% in the
general population.[1] NAFLD is not only associated with
increased liver-related mortality, but also with increased cardiac
mobility and mortality.[2,3] Earlier, we reported a significant
association between NAFLD and the presence of high-risk
plaques on coronary computed tomography angiography (CTA)
that increase the likelihood of cardiovascular events.[4] Emerging
evidence demonstrated that NAFLD represented a chronic low-
grade inflammatory state, characterized by elevated circulating
levels of cytokines and activation of pro-inflammatory signaling
pathways.[5,6] However, the underlying mechanisms of the
increased cardiac mortality in patients with NAFLD have not
been fully understood.
Vascular inflammation is linked to the development of
atherosclerosis and the pathogenesis of acute coronary syn-
drome.[7] Recently, pericoronary adipose tissue (PCAT) attenua-
tion on coronary CTA was introduced as a novel method to
identify localized coronary inflammation.[8] High PCAT attenu-
ation was found to be associated with the progression of non-
calcified plaque and total plaque volumes as determined with
coronary CTA.[9] In the Cardiovascular RISK Prediction using
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Computed Tomography (CRISP-CT) study, high PCAT attenua-
tion around the right coronary artery and left anterior descending
artery (LAD) and the right coronary artery (RCA) was shown to
be a significant risk factor for the increased cardiac mortality.[10]
To date, no study has been reported on the differences in
pericoronary vascular inflammation between patients with and
without NAFLD.
Therefore, the present study aimed to investigate the
association betweenNAFLD and PCAT attenuation as quantified
by coronary CTA.
2. Materials and methods
2.1. Study population
This case-control study was a sub-analysis of the prospective,
single-center registry that evaluated the impact of NAFLD on the
prognosis in patients with stable coronary artery disease (CAD)
undergoing coronary CTA at Okayama University Hospital.
Figure 1 shows the flow diagram of the study design. Three
hundred seventy one Japanese outpatients without a history of
CAD who underwent coronary CTA for suspected stable CAD
from January to December 2020 were enrolled. Stable CAD was
defined as angina with no changes in the frequency, duration, or
intensity of anginal symptoms within 4weeks before coronary
CTA. The patients who consumed >20g of alcohol per day (n=
42), with known liver disease (carriers of hepatitis B or C virus,
n=15), who were currently using oral corticosteroids (n=10)
were excluded from the study. Finally, 304 patients were included
in the study, of which 78 were diagnosed with NAFLD by
abdominal CT. Of the 226 non-NAFLD patients, 78 age- and
sex-matched patients were selected as the non-NAFLD group.
The study protocol was approved by the Institutional Review
Board of Okayama University Hospital and the study was
conducted in accordance with the principles of the Declaration of
Helsinki. All enrolled patients provided written informed
consent.
2.2. CT assessment of nonalcoholic fatty liver disease
Anabdominal non-contrast CT scanwasperformed just before the
cardiac scanon the sameday, as previously described.[2,11]Hepatic
and splenic Hounsfield attenuations were measured in the largest
possible regions. The regions of interest included 2 areas that were
aligned to the anterior-posterior dimension of the right liver lobe
and one that was aligned to the spleen. The hepatic-to-spleen
attenuation ratio was calculated using the mean Hounsfield unit
(HU) measurements of the 2 right liver lobe regions of interest. A
hepatic-to-spleen attenuation ratio of <1.0 was defined as the
cutoff for a positive diagnosis of hepatic steatosis.
2.3. Acquisition and analyses of coronary computed
tomography angiography images
CT scans were performed using a 128-slice CT scanner
(SOMATOM Definition Flash; Siemens Medical Solutions,
Erlangen, Germany) as previously described.[12] Coronary
CTA findings were interpreted by 2 experienced cardiovascular
imagers (K.I. and T.M.) who were blinded to clinical and CT
data. Plaque characteristics were defined in accordance with the
Society of Cardiovascular CT.[13] Significant coronary artery
stenosis was defined by a cross-sectional narrowing of >50%.
The vascular remodeling index was calculated by dividing the
cross-sectional lesion vessel area by the proximal reference vessel
area. Positive remodeling was defined as a remodeling index
>1.1. Plaques with a CT attenuation number of <50 HU were
defined as low-density plaques. Spotty calcification was defined
as a calcium burden length <1.5 times the vessel diameter and a
width less than two-thirds of the vessel diameter. High-risk
plaques were defined when 2 or more plaque characteristics,
Figure 1. Flowchart showing the study design. Among 371 Japanese outpatients without a history of CAD who underwent coronary CTA for suspected stable
CAD, those who consumed>20g of alcohol per day, with known liver disease (carriers of hepatitis B or C virus), and who were currently using oral corticosteroids
were excluded. A total of 78 patients were diagnosed with NAFLD, and 78 age- and sex- matched patients were selected as the non-NAFLD group from the
remaining 226 non-NAFLD patients. CAD = coronary artery disease, CTA = computed tomography angiography, NAFLD = non-alcoholic fatty liver disease.
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including positive remodeling, low-density plaques, and spotty
calcification were present, as previously described.[2]
2.4. Analysis of pericoronary adipose tissue attenuation
In all patients, PCAT attenuation was measured using a dedicated
workstation (Aquarius iNuition Edition version 4.4.13; TeraR-
econ Inc., Foster City, CA, USA). The semi-automated software
used in this study had been validated with respect to repeatability
before, showing a very good intra-observer and interobserver
agreement for the PCAT attenuation (intraclass correlation
coefficient 0.987 [P< .0001] and 0.980 [P< .0001], respective-
ly).[10] The standard measurements of PCAT attenuation around
the proximal LAD and the proximal RCA are the excellent
surrogates of the background vascular inflammation of the entire
coronary tree.[14] As shown in Figure 2A–F, the proximal 40mm
segments of the LAD and proximal 10 to 50mm segment of the
RCA were traced in an automated manner with the additional
manual adjustments to the automatic delineation of the coronary
vesselwall. PCATwasdefinedas the adipose tissue locatedwithin a
radial distance from the outer vessel wall equal to the diameter of
the coronary vessel, as described and validated previously.[8,15]
Adipose tissue was defined as all voxels with an attenuation
between 190 HU and 30 HU, and the PCAT attenuation was
automatically calculated as the mean CT attenuation value of
PCAT. PCAT attenuation analysis was performed by 2 inves-
tigators (T.M. andK.O.)whowere blinded to clinical andCTdata.
We measured the LAD-PCAT attenuation in all patients (n=156)
and the RCA-PCAT attenuation in 138 patients (88%) due to
hypoplasia of the RCA. Thus, in the present study, PCAT
attenuation surrounding the LAD was used for further analysis.
2.5. Statistical analysis
Continuous variables are expressed asmean± standarddeviationor
median with interquartile range. Dichotomous variables are
expressed as numbers (proportion). Differences in continuous
variables between the2groupswere analyzedby thepaired Student t
test or the Mann–Whitney U test, as appropriate. Categorical data
were compared by Chi-Squared analysis or Fisher exact test, based
on the category cell size. Univariable and multivariable logistic
regression analyzes were performed to evaluate the association
between NAFLD and high PCAT attenuation. In multivariable
logistic regression analysis, the associations were adjusted for the
variables. All reported P values were two-sided and P< .05 was
considered statistically significant. Statistical analyses were per-
formed using SPSS software (version 24; IBMCorp., Armonk,NY).
3. Results
3.1. Patient characteristics and coronary computed
tomography angiography findings according to
nonalcoholic fatty liver disease status
The mean age of the study population was 62years, and 75%
were males. The baseline characteristics of patients with and
without NAFLD are shown in Table 1. Patients with NAFLD had
Figure 2. PCAT using coronary CT angiography. Representative images of PCAT attenuation in patients with NAFLD (A–C) and without NAFLD (D–F). Semi-
automated software measurements showing color coded PCAT attenuation in axial view (A and C) and longitudinal view (B and D) around the proximal 40mmof the
LAD. PCAT attenuation was defined as the mean CT attenuation value (190 to 30 HU) within a radial distance equal to the diameter of the vessel. Histograms
demonstrated that the PCAT attenuation in the LAD was 64.1 HU and 79.2 HU in patients with and without NAFLD, respectively (C and F). The numbers of
patients with NAFLD (red bar) and without NAFLD (blue bar) are shown in the histograms (G). CT= computed tomography, HU=Hounsfield unit, LAD= left anterior
descending artery, NAFLD = non-alcoholic fatty liver disease, PCAT = pericoronary adipose tissue attenuation.
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a greater body mass index and a higher prevalence of
hypertension, diabetes mellitus, and obesity. Patients with
NAFLD also had higher levels of aspartate aminotransferase
(P= .002), alanine aminotransferase (P< .001), and glycated
hemoglobin A1c (P= .005) and lower levels of high-density
lipoprotein (P= .017) than those without NAFLD.
The mean PCAT attenuation in LAD and RCA was 72.9 HU
and 70.6 HU, respectively. The mean PCAT attenuation in
patients with NAFLD was significantly higher than that in patients
without NAFLD (LAD; 71.3±5.9 HU and 74.5±4.6 HU,
P< .001, RCA; -69.6±6.3HU and71.6±5.2HU, P= .038). The
histograms of LAD-PCAT attenuation are shown in Figure 2G. The
prevalence of high-risk plaques in LAD was significantly greater in
patientswithNAFLD than that in thosewithoutNAFLD (P= .042).
Nodifference in theprevalenceof significant stenosis in theLADwas
found between the 2 groups (P= .390).
3.2. Patient characteristics and coronary computed
tomography angiography findings according to
pericoronary adipose tissue attenuation
The patients were classified into 2 groups based on the median
value of the LAD-PCAT attenuation (72.5 HU): high PCAT
attenuation group (≥ 72.5 HU, n=78) and low PCAT
attenuation group (< 72.5HU, n=78). As shown in Table 2,
high PCAT attenuation was observed in male patients (P= .028)
and in patients with NAFLD (P= .001). With regard to coronary
CTA findings, no differences in the prevalence of high-risk
plaques (P= .114) and significant stenosis (P= .667) were found
between the high and low PCAT attenuation groups.
3.3. Association between nonalcoholic fatty liver disease
and pericoronary adipose tissue attenuation
As shown in Table 3, univariate logistic regression analysis
revealed that male sex and NAFLD were significantly associated
with high PCAT attenuation. In multivariate logistic regression
analysis, NAFLD was independently associated with high PCAT
attenuation with an odds ratio of 2.912 (95% confidence
interval: 1.386–6.118, P= .005) after adjustment for the
variables (age, sex, hypertension, diabetes mellitus, dyslipidemia,
smoking, obesity). In addition, NAFLD was independently
associated with high PCAT attenuation with an odds ratio of
2.851 (95% confidence interval [CI]: 1.340–6.068, P= .007)
after adjustment for the variables mentioned above plus coronary
CTA findings (high-risk plaques and significant stenosis). We
further analyzed the association between NAFLD and elevated
PCAT attenuation (≥ 70.1 HU, the cut-off value derived from
the previous study by Oikonomou et al [10]). NAFLD was
independently associated with elevated PCAT attenuation with
an odds ratio of 4.392 (95% confidence interval: 1.851–10.417,
P= .001) (Data not shown).
4. Discussion
To our knowledge, this is the first study to demonstrate that
NAFLDwas significantly associated with high PCAT attenuation
on coronary CTA. This result suggests that patients with NAFLD
have greater pericoronary inflammation as compared to patients
without NAFLD. Our findings may help identify underlying
mechanisms between NAFLD and cardiovascular events.
Chronic inflammation plays a critical role in the development
of atherosclerosis and plaque rupture leading to acute coronary
syndrome.[7] It is recognized that chronic low-grade systemic
inflammation is a key feature of NAFLD.[16] In the Framingham
Heart Study, the presence of liver fat measured by CT was linked
to the increased level of plasma inflammatory biomarkers.[5] In
addition, the levels of interleukin-6, high-sensitivity C-reactive
protein, and tumor necrosis factor-a have been reported to
increase in line with hepatic histological severity.[6,17] Thus,
NAFLD has a systemic foundation for the development of
atherosclerosis. On the other hand, high PCAT attenuation
Table 1





N 156 78 78
Age, yrs 62±11 62±12 63±11 .801
Males 116 (74) 58 (74) 58 (74) 1.000
Body mass index, kg/m2 26±4 27±3 25±3 <.001
Hypertension 94 (60) 58 (74) 36 (46) <.001
Diabetes mellitus 54 (35) 34 (44) 20 (26) .018
Dyslipidemia 88 (56) 47 (60) 41 (53) .333
Current smoker 44 (28) 24 (31) 20 (26) .477
†Obesity 82 (53) 54 (69) 28 (36) <.001
b blocker 34 (22) 19 (24) 15 (19) .438
Calcium channel blocker 57 (37) 37 (47) 20 (26) .005
ACE-I or ARB 67 (43) 42 (54) 25 (32) .006
Statin 48 (31) 31 (40) 17 (22) .015
LAD-PCAT attenuation, HU 72.9±5.5 71.3±5.9 74.5±4.6 <.001
High-risk plaques in LAD 41 (26) 28 (36) 13 (17) .006
Significant stenosis in LAD 41 (26) 24 (31) 17 (22) .203
Data are presented as mean ± standard deviation or number (%).
∗
Comparisons between patients with and wihtout NAFLD.
† Obesity was defined as body mass index≥25kg/m2.
ACE-I = angiotensin-converting enzyme inhibitor, ARB = angiotensin-receptor blocker, HU = Hounsfield units, LAD = left anterior descending artery, NAFLD = non-alcoholic fatty liver disease, PCAT =
pericoronary adipose tissue.
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represents changes in the PCAT composition driven by
inflammatory signals coming from the inflamed coronary artery.
The present study clearly demonstrated that NAFLD played an
important role not only in systemic inflammation but also in
localized coronary artery inflammation. Further studies are
needed to focus on the identification of the mechanisms linking
NAFLD to local vascular inflammation.
Our previous study showed that NAFLD was an independent
risk factor for high-risk coronary plaques that increase the
likelihood of acute coronary events.[4] We also demonstrated that
the incidence of acute coronary events and the presence of high-
risk plaques were significantly greater in patients with NAFLD
than in those without NAFLD.[2] However, the Incident
COronary EveNts Identified by Coronary Tomography (ICON-
IC) study demonstrated that the relationship between high-risk
plaques on coronary CTA and future cardiovascular events was
weak,[18] suggesting that the presence of high-risk plaques could
only partly explain the underlying mechanism of cardiovascular
events. Meanwhile, PCAT attenuation was reported to be linked
with cardiac mortality.[10] In the present study, the presence of
high-risk plaques was not significantly associated with high
PCAT attenuation, which is in line with previous data.[14] Our
findings suggest that high-risk plaques and high PCAT attenua-
tion capture different biological information, both of which
might be linked to cardiovascular events in NAFLD patients.
Despite the increasing number of NAFLD patients, there are
limited therapeutic approaches and no approved pharmacologi-
cal therapies for NAFLD.[16] Therefore, the management of
metabolic risk factors by lifestyle changes and pharmacological
therapies are the essential components for its prevention. Our
results suggest that the treatments which reduce PCAT attenua-
tion may potentially prevent CAD in patients with NAFLD.
Table 2







P valueN 78 78
Age, yrs 62±13 62±11 .951
Males 64 (82) 52 (67) .028
Body mass index, kg/m2 26±3 26±4 .951
Hypertension 29 (37) 25 (32) .501
Diabetes mellitus 42 (54) 46 (59) .518
Dyslipidemia 42 (54) 46 (59) .518
Current smoker 23 (30) 21 (27) .722
∗
Obesity 44 (56) 38 (49) .374
b blocker 13 (17) 21 (27) .121
Calcium channel blocker 27 (35) 30 (39) .618
ACE-I or ARB 37 (47) 30 (39) .258
Statin 24 (31) 24 (31) 1.000
eGFR, ml/min/1.73 m2 71±18 69±15 .536
AST, IU/L 27±14 25±9 .282
ALT, IU/L 32±18 28±16 .123
Total cholesterol, mg/dL 190±35 194±37 .548
LDL cholesterol, mg/dL 116±36 122±32 .287
HDL cholesterol, mg/dL 52±11 53±15 .637
Triglyceride, mg/dL 129 (97–190) 121 (98–189) .792
Hemoglobin A1c, % 6.5±1.2 6.2±0.9 .153
hsCRP, mg/dL 0.12 (0.06–0.22) 0.11 (0.06–0.30) .958
High-risk plaques in LAD 15 (19) 8 (10) .114
Significant stenosis in LAD 12 (15) 14 (18) .667
Data are presented as mean ± standard deviation, number (%), or median (25th–75th percentile).
∗
Obesity was defined as body mass index≥25kg/m2.
ACE-I = angiotensin-converting enzyme inhibitor, ALT = alanine aminotransferase, ARB =
angiotensin receptor blockers, AST = aspartate aminotransferase, eGFR = estimated glomerular
filtration rate, HDL = high-density lipoprotein, hsCRP = high-sensitivity C-reactive protein, HU =
Hounsfield units, LAD = left anterior descending artery, LDL = low-density lipoprotein, NAFLD = non-
alcoholic fatty liver disease, PCAT = pericoronary adipose tissue.
Table 3




Odds ratio (95% CI) P value Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age, per 1 yr 0.999 (0.973–1.026) .951 0.999 (0.968–1.031) .948 1.001 (0.969–1.034) .948
Male 2.286 (1.084–4.818) .030 2.528 (1.117–5.720) .026 2.674 (1.150–6.219) .022
Body mass index, per 1 kg/m2 0.997 (0.912–1.090) .951
Hypertension 1.537 (0.806–2.932) .192 1.179 (0.545–2.550) .677 1.154 (0.524–2.542) .722
Diabetes mellitus 1.255 (0.648–2.430) .501 1.055 (0.498–2.234) .889 1.127 (0.523–2.426) .760
Dyslipidemia 0.812 (0.431–1.530) .519 0.737 (0.366–1.486) .394 0.764 (0.373–1.565) .462
Current smoker 1.135 (0.722–2.281) .722 0.851 (0.387–1.867) .687 0.860 (0.381–1.937) .715
Obesity 1.362 (0.725–2.559) .337 1.014 (0.494–2.078) .971 1.094 (0.520–2.301) .813
Statin 1.000 (0.507–1.974) 1.000
eGFR, per 1 ml/min/1.73 m2 1.006 (0.987–1.025) .534
Total cholesterol, per 1 mg/dL 0.997 (0.988–1.006) .545
LDL cholesterol, per 1 mg/dL 0.995 (0.985–1.005) .285
HDL cholesterol, per 1 mg/dL 0.993 (0.967–1.021) .634
‡Log (Triglyceride), 1 index 1.139 (0.595–2.180) .694
Hemoglobin A1c, per 1% 1.263 (0.914–1.747) .157
‡Log (hsCRP), 1 index 0.898 (0.673–1.200) .468
NAFLD 2.855 (1.491–5.465) .002 2.912 (1.386–6.118) .005 2.749 (1.275–5.930) .010
High-risk plaques in LAD 1.828 (0.884–3.781) .104 1.979 (0.772–5.076) .155
Significant stenosis in LAD 0.820 (0.401–1.675) .82 0.444 (0.174–1.131) .089
∗
Multivariate-1 model was adjusted for age, sex, hypertension, diabetes mellitus, dyslipidemia, smoking, and obesity.
†Multivariate-2 model was adjusted for age, sex, hypertension, diabetes mellitus, dyslipidemia, smoking, obesity, high-risk plaques, and significant stenosis.
‡ Triglyceride and hsCRP were logarithm-transformed.
CI = confidence interval, eGFR = estimated glomerular filtration rate, HDL = high-density lipoprotein, HDL = high-density lipoprotein, hsCRP = high-sensitivity C-reactive protein, LAD = left anterior descending
artery, LDL = low-density lipoprotein, NAFLD = non-alcoholic fatty liver disease, PCAT = pericoronary adipose tissue.
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Statins are well established for the prevention of cardiovascular
events, and Dai et al reported that statin therapy over 1 year
decreased PCAT attenuation.[19] However, in our study, NAFLD
patients had a higher PCAT attenuation despite almost 40% of
patients taking statins, suggesting that further aggressive treat-
ments are needed. Bittner et al recently reported that high levels of
eicosapentaenoic acid are associated with lower PCAT attenua-
tion.[20] Considering the clinical trial data that pure eicosapen-
taenoic acid supplementation reduced low-attenuation coronary
plaque volume on coronary CTA,[21] omega-3 supplementation
would be a promising approach to reduce pericoronary
inflammation. Further studies are needed to investigate the
effects of these therapies on PCAT attenuation in NAFLD
patients and their clinical outcome.
Our study has some limitations that need to be addressed. First,
this is a single-center case-control study, and the sample size
was small. Our findings need to be confirmed with a larger
population. Second, our study population only consisted of
patients who were suspected of having stable CAD. Furthermore,
only Japanese patients were included. Although several studies on
non-Asian populations have recently been reported,[15,19] the
generalizability of our data to other ethnicities remains uncertain.
Third, we have not obtained the clinical outcome data yet;
therefore, the association between PCAT attenuation and
cardiovascular events is not determined.
In conclusion, our study demonstrated that NAFLD was
significantly associated with high PCAT attenuation on coronary
CTA, which may be considered as a novel marker of coronary
inflammation, independent of classical cardiovascular risk
factors. Our findings may help to identify underlying mechanisms
linking NAFLD to cardiovascular events.
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